Loading stock data…
FBRX
$24.59+0.30 (+1.24%)
Market OpenUpdated 12:42 PM EDT
Forte Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Forte Biosciences, Inc. in the Healthcare sector is trading at $24.59. Wall Street consensus targets $63.75 (4 analysts), implying a +159.3% move over the next 12 months. The stock is currently 31% below its 52-week high of $35.80, remaining 15.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +159.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$24.59
Potential Downside
0%
Whystock Fair Value$24.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$63.75+159.3%
Range$54.00 – $75.00
Fundamentals
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and aut...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$565.53M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.24%
Volume
Today's trading volume
65,300
Recent News
Top Midday Gainers
Ares Management (ARES) on Thursday agreed to acquire real estate investment trust Whitestone REIT (W
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Forte Biosciences...
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock
Investors who take an interest in Forte Biosciences, Inc. ( NASDAQ:FBRX ) should definitely note that the Chief...
Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year
Key Insights Significantly high institutional ownership implies Forte Biosciences' stock price is sensitive to their...